Transcutaneous Vagus Nerve Stimulation for the treatment of chronic migraine
Organizational Data
- DRKS-ID:
- DRKS00003681
- Recruitment Status:
- Recruiting complete, study complete
- Date of registration in DRKS:
- 2012-03-23
- Last update in DRKS:
- 2016-09-15
- Registration type:
- Prospective
Acronym/abbreviation of the study
cMPsCMI01
URL of the study
Brief summary in lay language
Invasive vagus nerve stimulation (VNS) is an approved treatment in drug-resistant epilepsy. The development of a medical device to apply transcutaneous vagus nerve stimulation (t-VNS) meets the demand for a non-invasive therapy with low side-effects. During t-VNS electrical pulses are delivered via electrodes which are placed on the skin of the outer ear. A reduction in epileptic seizure frequency is observed both after VNS and after the recently developed t-VNS. Furthermore several clinical case series describe a headache reducing effect of VNS. However, the method is not applied routinely for the treatment of headache at the moment. The study, which is going to begin in the near future, is conducted to elucidate the possible reduction in both the frequency and the intensity of migraine attacks after the application of the medical device. The patient will receive the non-invasive device from the investigator and apply it self-dependently for 4 to maximum 5 hours daily. The prophylactic efficacy of the therapy will be judged using a patient diary. Depending on his participation in the optional follow-up phase the patient will have to participate in 6 to 7 clinical visits during the study phase, which is going to last 4 to 7 months for each participant.
Brief summary in scientific language
Invasive vagus nerve stimulation (VNS) is an approved treatment in drug-resistant epilepsy. The t-VNS® technology, a non-invasive treatment, uses the fact that the auricular branch of the vagus nerve supplies the cymba conchae of the human ear exclusively. A specifically developed ear electrode guarantees that electrical impulses from the pulse generator, which is connected by cable, can be accurately delivered transcutaneously. The excitatory projection of the cervical and the auricular branches of the vagus nerve to the nucleus of the solitary tract has been shown to activate similar subcortical and cortical areas in the brain. Literature review shows several examples of cases where the invasive VNS seemed to be effective in treating different types of headache. Therefore, the study is going to be conducted in order to demonstrate t-VNS to be an effective option for the treatment of chronic migraine. The influence of t-VNS both on the frequency of migraine attacks and on the intensity of pain during these attacks as well as on the quality of life of patients are the most important outcome parameters of the clinical trial.
Health condition or problem studied
- ICD10:
- G43.3 - Complicated migraine
- Healthy volunteers:
- No Entry
Interventions, Observational Groups
- Arm 1:
- active group: transcutaneous, non-invasive electrical stimulation of the auricular branch of the vagus nerve by using a specific ear electrode. A cable connects this ear electrode with the stimulation unit, which has the size of a mobile phone. In the active arm impulses will be given in a high frequency.
- Arm 2:
- active control group: Stimulation with the same kind of medical device and at the same site as done in the active group, but with a lower impulse ferquency.
Endpoints
- Primary outcome:
- Proof a the therapeutic efficacy of t-VNS for chronic migraine estimated via the number of headache days per 28 days.
- Secondary outcome:
- Recording of the headache related burden. Recording of the amount of acute medication needed. Recording of the headache intensity. Recording of any adverse events of t-VNS. estimated via: headache intensity during headache days. Consumption of acute medication. Number of migraine related consultations. MIDAS. HIT-6-Score. Mode and number of AEs and SAEs.
Study Design
- Purpose:
- Treatment
- Allocation:
- Randomized controlled study
- Control:
-
- Active control (effective treatment of control group)
- Phase:
- N/A
- Study type:
- Interventional
- Mechanism of allocation concealment:
- No Entry
- Blinding:
- Yes
- Assignment:
- Parallel
- Sequence generation:
- No Entry
- Who is blinded:
-
- Assessor
- Caregiver
- Data analyst
- Investigator/therapist
- Patient/subject
Recruitment
- Recruitment Status:
- Recruiting complete, study complete
- Reason if recruiting stopped or withdrawn:
- No Entry
Recruitment Locations
- Recruitment countries:
-
- Germany
- Number of study centers:
- Monocenter study
- Recruitment location(s):
-
- University medical center Oberbayerisches Kopfschmerzzentrum der LMU München München
Recruitment period and number of participants
- Planned study start date:
- 2012-04-16
- Actual study start date:
- 2012-04-17
- Planned study completion date:
- No Entry
- Actual Study Completion Date:
- 2014-11-30
- Target Sample Size:
- 98
- Final Sample Size:
- 46
Inclusion Criteria
- Sex:
- All
- Minimum Age:
- 18 Years
- Maximum Age:
- 70 Years
- Additional Inclusion Criteria:
- males and females from 18 to 70 y. Patients suffering from chronic migraine according to ICHD-II 1.5.1. Duration of disease of minimum 3 months. Prophylactic medication on a stable regimen for minimum 1 month or 5 half-lives (the longer duration will be counted). Stable agent(s) for acute medication during baseline period. Patient diary kept properly for minimum 20 out of 28 days, minimum 15 headache days with minimum 4 hours of headache, extrapolation to 28 days.
Exclusion Criteria
Participation in another clinical trial during the last 4 weeks before study entry. Pregnant or breastfeeding women. Suffering from craniomandibular dysfunction or fibromyalgia. Other primary/secondary headache disorders (e.g. cluster headache, trigeminal neuralgia, etc.). Beck depression inventory > 24 at date of inclusion. Other chronic neurological or psychiatric disorders (e.g. psychoses) which impair study participation. Dependance on opioids or benzodiazepines. Anatomical or pathological abnormalities at the left ear. Actual process of retirement.
Addresses
Primary Sponsor
- Address:
- cerbomed GmbHDr. Andreas HartlepHenkestr. 9191052 ErlangenGermany
- Telephone:
- No Entry
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
- Investigator Sponsored/Initiated Trial (IST/IIT):
- No
Contact for Scientific Queries
- Address:
- cerbomed gmbHDr. Andreas HartlepHenkestr. 9191052 ErlangenGermany
- Telephone:
- +49 9131 9202 760
- Fax:
- +49 9131 9202 7692
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cerbomed.com
Contact for Public Queries
- Address:
- Oberbayerisches Kopfschmerzzentrum der LMU MünchenPD Dr. med. Ruth RuscheweyhMarchioninistr. 1581377 MünchenGermany
- Telephone:
- +49 89 7095 3907
- Fax:
- +49 89 7095 3677
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Neurologie/de/Klinik/Neurologische_Poliklinik/Kopfschmerz_-_Ambulanz/index.html
Principal Investigator
- Address:
- cerbomed gmbHDr. Andreas HartlepHenkestr. 9191052 ErlangenGermany
- Telephone:
- +49 9131 9202 760
- Fax:
- +49 9131 9202 7692
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.cerbomed.com
Sources of Monetary or Material Support
Commercial (pharmaceutical industry, medical engineering industry, etc.)
- Address:
- cerbomed GmbHHenkestr. 9191052 ErlangenGermany
- Telephone:
- No Entry
- Fax:
- No Entry
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Ethics Committee
Address Ethics Committee
- Address:
- Ethikkommission der Med. Fakultät der LMUPettenkoferstraße 880336 MünchenGermany
- Telephone:
- +49-89-440055191
- Fax:
- +49-89-440055192
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Vote of leading Ethics Committee
- Vote of leading Ethics Committee
- Date of ethics committee application:
- 2011-09-26
- Ethics committee number:
- 510-11
- Vote of the Ethics Committee:
- Approved
- Date of the vote:
- 2012-02-08
Further identification numbers
- Other primary registry ID:
- No Entry
- EudraCT Number:
- No Entry
IPD - Individual Participant Data
- Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
- No Entry
- IPD Sharing Plan:
- No Entry
Study protocol and other study documents
- Study protocols:
- No Entry
- Study abstract:
- No Entry
- Other study documents:
- No Entry
- Background literature:
- No Entry
- Related DRKS studies:
- No Entry
Publication of study results
- Planned publication:
- No Entry
- Publikationen/Studienergebnisse:
- t-VNS in patients with chronic migraine
- Date of first publication of study results:
- No Entry
- DRKS entry published for the first time with results:
- No Entry
Basic reporting
- Basic Reporting / Results tables:
- No Entry
- Brief summary of results:
- No Entry